The emerging role of HDL in glucose metabolism

Nature Reviews Endocrinology

Volumn 8, Issue 4, 2012, Pages 237-245

  Drew, Brian G ^a   Rye, Kerry Anne ^b   Duffy, Stephen J ^c   Barter, Philip ^b   Kingwell, Bronwyn A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; DALCETRAPIB; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NICOTINIC ACID; TORCETRAPIB; TRIACYLGLYCEROL;

AEROBIC EXERCISE; ANTIINFLAMMATORY ACTIVITY; CELL FUNCTION; DIET THERAPY; ENDOPLASMIC RETICULUM; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; LIPOPROTEINS, HDL;

EID: 84858706253     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.235     Document Type: Review

References (111)

1. Barter, P. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301-1310 (2007).
2. Gordon, D. J. & Rifkind, B. M. High-density lipoprotein-the clinical implications of recent studies. N. Engl. J. Med. 321, 1311-1316 (1989).
3. Barter, P. J. et al. Antiinflammatory properties of HDL. Circ. Res. 95, 764-772 (2004).
4. Patel, S. et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol. 53, 962-971 (2009).
5. Navab, M. et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41, 1495-1508 (2000).
6. Navab, M. et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41, 1481-1494 (2000).
7. Calkin, A. C. et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120, 2095-2104 (2009).
8. Drew, B. G., Fidge, N. H., Gallon-Beaumier, G., Kemp, B. E. & Kingwell, B. A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl Acad. Sci. USA 101, 6999-7004 (2004).
9. Yuhanna, I. S. et al. High-density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat. Med. 7, 853-857 (2001).
10. Brunham, L. R. et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13, 340-347 (2007).
11. Abderrahmani, A. et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50, 1304-1314 (2007).
12. Drew, B. G. et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119, 2103-2111 (2009).
13. Fryirs, M. A. et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol. 30, 1642-1648 (2010).
14. Han, R. et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50, 1960-1968 (2007).
15. Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119 (2005).
16. Koseki, M. et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J. Atheroscler. Thromb. 16, 292-296 (2009).
17. Vergeer, M. et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 33, 869-874 (2010).
18. Daimon, M. et al. Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem. Biophys. Res. Commun. 329, 205-210 (2005).
19. Villarreal-Molina, M. T. et al. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes 57, 509-513 (2008).
20. Zhong, S. et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923 (1996).
21. López-Ríos, L. et al. Association of Taq 1B CETP polymorphism with insulin and HOMA levels in the population of the Canary Islands. Nutr. Metab. Cardiovasc. Dis. 21, 18-24 (2011).
22. Ruan, X. et al. Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J. Cell. Mol. Med. 15, 763-772 (2011).
23. Sturek, J. M. et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J. Clin. Invest. 120, 2575-2589 (2010).
24. Cannon, C. P. et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363, 2406-2415 (2010).
25. Drexel, H. et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28, 101-107 (2005).
26. Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
27. Gatti, A. et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 32, 1550-1552 (2009).
28. Haffner, S. M., Stern, M. P., Hazuda, H. P., Mitchell, B. D. & Patterson, J. K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263, 2893-2898 (1990).
29. Buijsse, B., Simmons, R. K., Griffin, S. J. & Schulze, M. B. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol. Rev. 33, 46-62 (2011).
30. Bozorgmanesh, M., Hadaegh, F., Ghaffari, S., Harati, H. & Azizi, F. A simple risk score effectively predicted type 2 diabetes in Iranian adult population: population-based cohort study. Eur. J. Public Health 21, 554-559 (2011).
31. Dhanaraj, E. et al. Predictors of metabolic syndrome in Asian north Indians with newly detected type 2 diabetes. Indian J. Med. Res. 129, 506-514 (2009).
32. Fagot-Campagna, A. et al. HDL cholesterol subfractions and risk of developing type 2 diabetes among Pima Indians. Diabetes Care 22, 271-274 (1999).
33. Schulze, M. B. et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 32, 2116-2119 (2009).
34. von Eckardstein, A., Schulte, H. & Assmann, G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster. J. Clin. Endocrinol. Metab. 85, 3101-3108 (2000).
35. Franks, P. W. et al. Childhood predictors of young-onset type 2 diabetes. Diabetes 56, 2964-2972 (2007).
36. Schmidt, M. I. et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 28, 2013-2018 (2005).
37. Aekplakorn, W. et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care 29, 1872-1877 (2006).
38. Wilson, P. W. et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch. Intern. Med. 167, 1068-1074 (2007).
39. Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
40. Brunzell, J. D. & Hokanson, J. E. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 22 (Suppl. 3), C10-C13 (1999).
41. Ginsberg, H. N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453-458 (2000).
42. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
43. Murao, K. et al. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J. Biol. Chem. 273, 18959-18965 (1998).
44. Mooradian, A. D., Haas, M. J. & Wong, N. C. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 53, 513-520 (2004).
45. Haas, M. J., Pun, K., Reinacher, D., Wong, N. C. & Mooradian, A. D. Effects of ketoacidosis on rat apolipoprotein A1 gene expression: a link with acidosis but not with ketones. J. Mol. Endocrinol. 25, 129-139 (2000).
46. Haas, M. J., Reinacher, D., Li, J. P., Wong, N. C. & Mooradian, A. D. Regulation of apoA1 gene expression with acidosis: requirement for a transcriptional repressor. J. Mol. Endocrinol. 27, 43-57 (2001).
47. Borggreve, S. E., De Vries, R. & Dullaart, R. P. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 33, 1051-1069 (2003).
48. Pont, F., Duvillard, L., Florentin, E., Gambert, P. & Vergès, B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int. J. Obes. Relat. Metab. Disord. 26, 1151-1158 (2002).
49. Vajo, Z., Terry, J. G. & Brinton, E. A. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis 160, 495-501 (2002).
50. Berthezene, F. Non-insulin dependent diabetes and reverse cholesterol transport. Atherosclerosis 124 (Suppl.), S39-S42 (1996).
51. Hoang, A. et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50, 1770-1779 (2007).
52. Calvo, C., Ponsin, G. & Berthezene, F. Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabetes Metab. 14, 264-269 (1988).
53. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881-885 (2007).
54. Kooner, J. S. et al. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat. Genet. 43, 984-989 (2011).
55. 1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 124, 555-562 (2011).
56. Fielding, C. J. & Fielding, P. E. Cellular cholesterol efflux. Biochim. Biophys. Acta 1533, 175-189 (2001).
57. Oram, J. F. & Vaughan, A. M. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99, 1031-1043 (2006).
58. Kennedy, M. A. et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell. Metab. 1, 121-131 (2005).
59. Zhu, X. et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J. Biol. Chem. 283, 22930-22941 (2008).
60. Sun, Y. et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ. Res. 104, 455-465 (2009).
61. Yvan-Charvet, L. et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J. Lipid Res. 49, 107-114 (2008).
62. Senokuchi, T. et al. Forkhead transcription factors (FoxOs) promote apoptosis of insulin-resistant macrophages during cholesterol-induced endoplasmic reticulum stress. Diabetes 57, 2967-2976 (2008).
63. Yvan-Charvet, L. et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117, 3900-3908 (2007).
64. Matveyenko, A. V., Gurlo, T., Daval, M., Butler, A. E. & Butler, P. C. Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes 58, 906-916 (2009).
65. Nofer, J. R. et al. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem. Biophys. Res. Commun. 310, 98-103 (2003).
66. Kimura, T. et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281, 37457-37467 (2006).
67. McGrath, K. C. et al. Role of 3beta-hydroxysteroid-delta24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 29, 877-882 (2009).
68. Murphy, A. J. et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28, 2071-2077 (2008).
69. Yvan-Charvet, L. et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328, 1689-1693 (2010).
70. von Eckardstein, A. & Sibler, R. A. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr. Opin. Lipidol. 22, 26-32 (2011).
71. Hao, M., Head, W. S., Gunawardana, S. C., Hasty, A. H. & Piston, D. W. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56, 2328-2338 (2007).
72. Ishikawa, M. et al. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J. Lipid Res. 49, 2524-2534 (2008).
73. Iwasaki, Y. et al. Nuclear SREBP-1a causes loss of pancreatic beta-cells and impaired insulin secretion. Biochem. Biophys. Res. Commun. 378, 545-550 (2009).
74. Rütti, S. et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150, 4521-4530 (2009).
75. Vikman, J., Jimenez-Feltström, J., Nyman, P., Thelin, J. & Eliasson, L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J. 23, 58-67 (2009).
76. Esposito, K., Giugliano, D., Nappo, F. & Marfella, R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110, 214-219 (2004).
77. Ceriello, A. et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53, 701-710 (2004).
78. Monnier, L. et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681-1687 (2006).
79. Nalysnyk, L., Hernandez-Medina, M. & Krishnarajah, G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes. Metab. 12, 288-298 (2010).
80. Varma, V. et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am. J. Physiol. Endocrinol. Metab. 296, E1300-E1310 (2009).
81. Hotamisligil, G. S. & Erbay, E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 8, 923-934 (2008).
82. Chavez, J. A. et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 278, 10297-10303 (2003).
83. Montell, E. et al. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am. J. Physiol. Endocrinol. Metab. 280, E229-E237 (2001).
84. Nguyen, M. T. et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279-35292 (2007).
85. Samokhvalov, V., Bilan, P. J., Schertzer, J. D., Antonescu, C. N. & Klip, A. Palmitate- and lipopolysaccharide-activated macrophages evoke contrasting insulin responses in muscle cells. Am. J. Physiol. Endocrinol. Metab. 296, E37-E46 (2009).
86. Muscat, G. E. et al. Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors. J. Biol. Chem. 277, 40722-40728 (2002).
87. Zhang, Y. et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121, 1347-1355 (2011).
88. Lavelle-Jones, M., Scott, M. H., Kolterman, O., Moossa, A. R. & Olefsky, J. M. Non-insulin-mediated glucose uptake predominates in postabsorptive dogs. Am. J. Physiol. 252, E660-E666 (1987).
89. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001).
90. Kemp, B. E. et al. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 24, 22-25 (1999).
91. Kimura, T. et al. Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J. Biol. Chem. 285, 4387-4397 (2010).
92. Li, J. et al. Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pathway. J. Cell. Mol. Med. 14, 1083-1087 (2010).
93. Zhang, Q. et al. High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS ONE 6, e23556 (2011).
94. Kodama, S. et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch. Intern. Med. 167, 999-1008 (2007).
95. Kraus, W. E. et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N. Engl. J. Med. 347, 1483-1492 (2002).
96. Nilsson, P., Lundgren, H., Söderström, M., Fagerström, K. O. & Nilsson-Ehle, P. Effects of smoking cessation on insulin and cardiovascular risk factors-a controlled study of 4 months' duration. J. Intern. Med. 240, 189-194 (1996).
97. Dixon, J. B., Anderson, M., Cameron-Smith, D. & O'Brien, P. E. Sustained weight loss in obese subjects has benefits that are independent of attained weight. Obes. Res. 12, 1895-1902 (2004).
98. McLaughlin, T. et al. Persistence of improvement in insulin sensitivity following a dietary weight loss programme. Diabetes Obes. Metab. 10, 1186-1194 (2008).
99. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
100. Ginsberg, H. N. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
101. Tenenbaum, A. et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109, 2197-2202 (2004).
102. Tenenbaum, H. et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 194, 265-271 (2007).
103. Elam, M. B. et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284, 1263-1270 (2000).
104. McCormack, P. L. & Keating, G. M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65, 2719-2740 (2005).
105. Rajpathak, S. N. et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32, 1924-1929 (2009).
106. Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742 (2010).
107. Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556-2564 (2011).
108. Heinecke, J. W. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J. Clin. Lipidol. 4, 371-375 (2011).
109. Vaisar, T. et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117, 746-756 (2007).
110. Bensinger, S. J. et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134, 97-111 (2008).
111. Mendez, A. J. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion. J. Lipid Res. 38, 1807-1821 (1997).